Real-World mCSPC First-Line Treatment Intensification Remains Low
Investigators probed use of standard-of-care first-line metastatic castration-sensitive prostate cancer (mCSPC) treatment intensification.
Stay updated with breaking news from Optum Research Database. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investigators probed use of standard-of-care first-line metastatic castration-sensitive prostate cancer (mCSPC) treatment intensification.
First-line pembrolizumab-axitinib leads to lower health care resource utilization than ipilimumab-nivolumab in metastatic renal cell carcinoma.
The researchers conducted a retrospective cohort study using claims data from the Optum Research Database for 538 patients at least 6 years of age who initiated mepolizumab treatment for asthma between January 2016 and December 2019.
Mepolizumab use reduced exacerbations and the use of oral corticosteroids in patients with both allergic and non-allergic asthma.
First-line pembrolizumab-axitinib leads to lower health care resource utilization than ipilimumab-nivolumab in metastatic renal cell carcinoma.